6 unchanged sentences
(incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed October 6, 2020).
−Removed: Modification of Contract between the Company and the Department of Defense, United States of America, dated March 18, 2022 (portions of this exhibit (indicated by asterisks) have been redacted in compliance with Regulation S-K Item 601(b)(10)(iv)).
+Added: Second Amended and Restated Non-Employee Director Compensation Policy, effective as of June 15, 2022 .
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Interactive Data File (Form 10-Q for the Quarterly Period ended March 31, 2022 filed in XBRL).
+Added: Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2022 filed in XBRL).
The financial information contained in the XBRL-related documents is "unaudited"
6 unchanged sentences
IMMUNOME, INC.
+Added: August 5, 2022
/s/ Purnanand D.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 5, 2022
/s/ Corleen M.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.